ERBB2 and breast cancer: Analysis of individual biomarker expression (ER, PR, Ki67 and HER2) in primary breast cancer and synchronous lymph node metastases has shown that there is a small fraction of discordant cases but the prognostic implication for the individual patient is not settled [14,17-19].